Neoadjuvant PD-1 blockade with dostarlimab achieved high rates of organ preservation in patients with early-stage mismatch ...

New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding surgery and harsh treatments.

Jose B. Lingad Memorial General Hospital Head and Neck Cancer Specialist Paulyn Gaddi urges the public to practice healthy ...

Generally, the standard treatment for solid tumors is surgery. However, a recent study from New York City-based Memorial Sloan Kettering Cancer Center found immunotherapy can effectively treat these ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

New results from a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK), gastrointestinal oncologists Andrea ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during ...

Thyroid nodules are mostly benign lesions within the thyroid, with a small percentage being malignant. The decision for surgery is mainly based on the fine needle aspiration (FNA) cytology report, ...